Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer

NCT01208051 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

127

Enrollment

NIH

Sponsor class

Conditions

Refractory Differentiated Thyroid Gland Carcinoma
Refractory Thyroid Gland Follicular Carcinoma
Refractory Thyroid Gland Hurthle Cell Carcinoma
Refractory Thyroid Gland Papillary Carcinoma
Unresectable Thyroid Gland Carcinoma

Interventions

DRUG: Cediranib
DRUG: Cediranib Maleate
OTHER: Laboratory Biomarker Analysis
DRUG: Lenalidomide

Sponsor

National Cancer Institute (NCI)